Literature DB >> 25857587

Anti-osteoporotic activity of puerarin 6"-O-xyloside on ovariectomized mice and its potential mechanism.

Hai Li1, Bingpu Chen2, Guangfu Pang3, Jianhai Chen1, Jisheng Xie1, Hailing Huang1.   

Abstract

CONTEXT: Osteoporosis is one of the most common bone diseases, and radix of Pueraria lobata (Willd.) Ohwi possesses an obvious therapeutical effect on postmenopausal osteoporosis.
OBJECTIVE: This study investigates the anti-osteoporotic activity of the puerarin 6"-O-xyloside (PXY) on ovariectomized mice and its related mechanism.
MATERIALS AND METHODS: Osteoporotic mice model was established by ovariectomy (OVX). A total of 50 mice were divided into five groups (n = 10): sham, OVX group, PXY treatment groups (20, 40, and 60 mg/kg/d, i.p.). After 12 weeks' treatment, body weights were recorded. Then, mice were sacrificed, and serum samples were collected to determine the blood calcium, blood phosphorus, alkaline phosphatase (ALP), and osteoprotegerin (OPG) concentrations and uterine index was assayed. The thigh-bones of mice were collected to evaluate histopathological changes. In the in vitro experiment, the effect of PXY on osteoblasts' proliferation was evaluated and western blotting was performed to determine expressions of OPG and the receptor activators of NF-κB ligand (RANKL), as well as the ratio of OPG/RANKL.
RESULTS: PXY (40 and 60 mg/kg/d, i.p.) obviously decreased body weights and increased uterine index of OVX (p < 0.05), and improved osteoporotic syndromes of OVX mice; PXY also significantly increased the concentrations of blood calcium, blood phosphorus, ALP, and OPG of OVX mice (p < 0.05); moreover, PXY obviously up-regulated the ratio of OPG/RANKL (p < 0.05).
CONCLUSION: Our results demonstrated that the puerarin 6"-O-xyloside possesses significant anti-osteoporotic activity on ovariectomy mice.

Entities:  

Keywords:  OPG/RANKL; OVX; osteoblasts; radix of Pueraria lobata (willd.) ohwi

Mesh:

Substances:

Year:  2015        PMID: 25857587     DOI: 10.3109/13880209.2015.1017885

Source DB:  PubMed          Journal:  Pharm Biol        ISSN: 1388-0209            Impact factor:   3.503


  5 in total

1.  Anti-osteoporotic effects of Pueraria candollei var. mirifica on bone mineral density and histomorphometry in estrogen-deficient rats.

Authors:  Sarocha Suthon; Sukanya Jaroenporn; Narattaphol Charoenphandhu; Panan Suntornsaratoon; Suchinda Malaivijitnond
Journal:  J Nat Med       Date:  2016-01-27       Impact factor: 2.343

Review 2.  Natural Products from Chinese Medicines with Potential Benefits to Bone Health.

Authors:  Chun-Tao Che; Man Sau Wong; Christopher Wai Kei Lam
Journal:  Molecules       Date:  2016-02-27       Impact factor: 4.411

3.  Mapping theme trends and recognizing hot spots in postmenopausal osteoporosis research: a bibliometric analysis.

Authors:  Siming Zhou; Zhengbo Tao; Yue Zhu; Lin Tao
Journal:  PeerJ       Date:  2019-11-25       Impact factor: 2.984

4.  Effect of Puerarin on Osteogenic Differentiation in vitro and on New Bone Formation in vivo.

Authors:  Yanran Yang; Daiyun Chen; Yilin Li; Jinghua Zou; Ruiqi Han; Hongkun Li; Jun Zhang
Journal:  Drug Des Devel Ther       Date:  2022-08-27       Impact factor: 4.319

5.  Puerarin 6″-O-xyloside suppressed HCC via regulating proliferation, stemness, and apoptosis with inhibited PI3K/AKT/mTOR.

Authors:  Long Li; Jun-Dong Liu; Guo-Dong Gao; Kai Zhang; Yu-Wei Song; Hong-Bo Li
Journal:  Cancer Med       Date:  2020-07-21       Impact factor: 4.452

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.